8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  November 8, 2017 (November 8, 2017)

CHEMBIO DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	0-30379	88-0425691
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	3661 Horseblock Road
	Medford, NY 11763
	(Address of principal executive offices)
	631-924-1135
	(Registrant's Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01.  REGULATION FD DISCLOSURE.

On November  8, 2017, the Company issued a press release entitled "Chembio Diagnostics Reports Third Quarter 2017 Financial Results".   A copy of the press release is furnished herewith as Exhibit 99.1

On November 8, 2017, the Company posted a PowerPoint Presentation to their website entitled "Investor Presentation November, 2017."  A copy of the presentation is furnished herewith as Exhibit 99.2.

In addition, also on November 8, 2017, the Company posted an Investor Fact Sheet to their website.  A copy of the fact sheet is furnished herewith as Exhibit 99.3

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS

Exhibit Number	Description
99.1	Press Release entitled "Chembio Diagnostics Reports Third Quarter 2017 Financial Results" dated November 8, 2017
99.2	Presentation entitled "Investor Presentation November 2017" dated  November 8, 2017
99.3	Investor Fact Sheet posted to the company website dated November 8, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

November 8, 2017          Chembio Diagnostics, Inc.

By:    By:    /s/ John J. Sperzel III                                      

                    John J. Sperzel III

    Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release entitled "Chembio Diagnostics Reports Third Quarter 2017  Financial Results" dated November 8, 2017
99.2	Presentation entitled "Investor Presentation November, 2017" dated  November 8, 2017
99.3	Investor Fact Sheet posted to the company website dated November 8, 2017

EX-99.1

Chembio Diagnostics Reports Third Quarter 2017 Financial Results

Conference Call and Webcast Today at 4:30 p.m. Eastern Time

MEDFORD, NY, November 8, 2017 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, today reported financial results for the third quarter ended September 30, 2017.

John J. Sperzel, III, Chembio's President and CEO, stated, "During the third quarter of 2017, the Company continued to make progress with each of its key objectives: 1) strengthening the core sexually transmitted disease business, 2) building a broad tropical and fever disease portfolio, and 3) building a global commercial team.

"With respect to the Company's sexually transmitted disease business, Chembio increased total HIV product sales during the third quarter of 2017 by 273% compared to the prior year period, achieving HIV product sales growth in the United States, Latin America, Europe and Africa. In the U.S., the Company continues to prioritize development of its DPP^® HIV-Syphilis Assay in response to the global concerns related to HIV and Syphilis co-infection and mother-to-child transmission. We expect to complete the U.S. clinical trial for our DPP^® HIV-Syphilis Assay by year-end, in preparation for the FDA submission, which we believe keeps us on track to be the first to market a combination HIV-Syphilis Assay in the U.S.  Outside the U.S., Chembio experienced significant growth in its HIV Self-Test business, resulting in 219% year-over-year growth through the first three quarters.

"Turning to our tropical and fever disease business, the Company advanced its DPP® Malaria and DPP® Dengue Assays during the third quarter. It is important to note that these two diseases account for approximately 600 million cases annually. The field evaluation of our DPP® Malaria Assay, which previously received funding from the Bill & Melinda Gates Foundation, was completed during the third quarter, and we plan to begin commercialization of this ultra-sensitive test during 2018. We previously initiated sales of our DPP® Dengue Assay, including CDC's pilot program for our DPP® Dengue/Zika/Chikungunya Assay in four countries: India, Peru, Haiti and Guatemala.

"We also reached important regulatory milestones during the third quarter of 2017. In July, Chembio's DPP® Zika System, including the DPP® Micro Reader, was approved by Brazil's Health Regulatory Agency. In September, Chembio became the first company to receive U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for a rapid Zika test. The Company's U.S. DPP® Zika project has been funded with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Contract No. HHSO100201600022C."

Addressing the Company's financial results, Mr. Sperzel commented, "During the third quarter of 2017, Chembio achieved total revenue of $7.6 million, which represents a 102% increase over the prior-year period and the fourth highest quarter in Company history. Product sales during the third quarter of 2017 were $6.1 million, which represents a 145% increase over the prior-year period. During the first nine months of 2017, Chembio achieved total revenue of $18.0 million, which represents a 32% increase over the prior-year period. Product sales during the first nine months of 2017 were $14.4 million, which represents a 38% increase over the prior-year period. The sales growth achieved in several target regions during the third quarter of 2017, compared to the prior-year period, including a 386% increase in Latin America, a 100% increase in Africa, a 32% increase in the United States, and a 27% increase in Europe, further validates the strength and effectiveness of our global sales organization."

Summary Financial Information comparing the 2017 three-month third quarter to the 2016 third quarter:

· Total revenues of $7.6 million, compared with $3.7 million (an increase of 102.5%).

· Product sales of $6.1 million, compared with $2.5 million (an increase of 145.1%).

· Operating loss of $0.6 million, compared with operating loss of $2.1 million.

· Net loss of $0.6 million, or $0.05 per diluted share, compared with net loss of $2.1 million, or $0.19 per diluted share. 

Summary Financial Information comparing the first nine months of 2017 to the first nine months of 2016:

· Total revenues of $18.0 million, compared with $13.6 million (an increase of 32.4%).

· Product sales of $14.5 million, compared with $10.5 million (an increase of 38.3%).

· Operating loss of $4.4 million, compared with operating loss of $5.0 million.

· Net loss of $4.4 million, or $0.36 per diluted share, compared with net loss of $10.8, or $1.06 per diluted share.  The net loss in the 2016 period includes a tax provision for the recording of a valuation allowance on the Company's deferred tax asset of $5.8 million.

Additional Financial Information:

Third Quarter:

Total revenues in the 2017 third quarter of $7.6 million increased 102.5% compared with $3.7 million in the prior-year period. Product sales in the 2017 third quarter of $6.1 million increased 145.1% compared with $2.5 million in the prior-year period.  R&D milestone, and grant and royalty revenues in the 2017 third quarter of $1.5 million increased 16.9% compared with $1.2 million in the prior-year period.

Gross margin dollars in the 2017 third quarter of $3.5 million increased 80.5% compared with $2.0 million in the prior-year period, due primarily to increased product sales. Product gross margin dollars in the 2017 third quarter of $2.1 million increased 192.2% compared with $0.7 million in the prior-year period, which also was primarily due to increased product revenues.

R&D expenses in the 2017 third quarter of $1.8 million decreased 20.2%, compared with $2.3 million in the prior-year period.  Selling, general and administrative expenses in the 2017 third quarter of $2.3 million increased 25.8% compared with $1.8 million in the prior-year period, largely due to investments made to the scale-up of our sales and marketing organization globally, and professional fees.

Operating loss in the 2017 third quarter was $0.6 million, compared with an operating loss of $2.1 million in the prior-year period.

Net loss in the 2017 third quarter was $0.6 million, or $0.05 per diluted share, compared with net loss of $2.1 million, or $0.19 per diluted share, in the prior-year period. 

First Nine Months:

Total revenues in the 2017 first nine months of $18.0 million increased 32.4% compared with $13.6 million in the prior-year period. Product sales in the 2017 first nine months of $14.5 million increased 38.3% compared with $10.5 million in the prior-year period.  R&D milestone, and grant and royalty revenues in the 2017 first nine months of $3.6 million increased 13.1% compared with $3.2 million in the prior-year period.

Gross margin dollars in the 2017 first nine months of $8.5 million increased 27.5% compared with $6.7 million in the prior-year period, due primarily to the increase in product sales. The amount of product gross margin in the 2017 first nine months of $5.0 million increased 40.4% compared with $3.5 million in the prior-year period, which also was primarily due to increased product revenues.

R&D expenses in the 2017 first nine months of $6.0 million decreased 3.7%, compared with $6.3 million in the prior-year period.  Selling, general and administrative expenses in the 2017 first nine months of $6.9 million increased 27.1%, compared with $5.4 million in the prior-year period, largely due to investments made to scale up our sales and marketing organization globally, and professional fees.

Operating loss in the 2017 first nine months was $4.4 million, compared with an operating loss of $5.0 million in the prior-year period.

Net loss in the 2017 first nine months was $4.4 million, or $0.36 per diluted share, compared with net loss of $10.8 million, or $1.06 per diluted share, in the prior-year period.  The net loss in the 2016 period includes a tax provision for the recording of a valuation allowance on the Company's deferred tax asset of $5.8 million.

Balance Sheet Highlights:

The Company had cash and cash equivalents of $1.9 million as of September 30, 2017, compared with $10.6 million as of December 31, 2016. The decrease was primarily due to net cash used in operating activities of $7.2 million. Our working capital decreased by $4.9 million from $14.7 million as of December 31, 2016 to $9.8 million, largely due to cash used in operating activities and in investing activities, primarily for the acquisition in RVR Diagnostics Sdn Bhd, for the nine months of 2017.  Subsequent to that acquisition, we have changed the name of RVR Diagnostics Sdn Bhd to Chembio Diagnostics Malaysia Sdn Bhd.

Conference Call

To participate on the conference call, please dial (888) 567-1602 from the U.S. or (404) 267-0373 from outside the U.S.  To listen live via the Internet, please visit the Investor Relations section of Chembio's website at www.chembio.com.

To listen to a replay of the call, which will be accessible until November 15, 2017 at 11:59 p.m. ET, please dial (877) 481-4010 from the U.S. or (919) 882-2331 from outside the U.S., and enter conference ID #:22282.  An archive of the webcast will be available for 90 days on the Company's website at www.chembio.com.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets each of its DPP^® HIV 1/2 Assay, HIV 1/2 STAT-PAK^® Assay, and SURE CHECK^® HIV 1/2 Assay, with these Chembio brand names, in the U.S. and internationally, and its STAT-VIEW® Assay in Europe, both directly and through third-party distributors. 

Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.

Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Each of Chembio Diagnostic Systems, Inc. and Chembio Diagnostics Malaysia Sdn Bhd (formerly known as RVR Diagnostics Sdn Bhd) is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

(Tables to follow)

Contacts:

Vida Strategic Partners (investor relations)

Stephanie C. Diaz

(415) 675-7401

sdiaz@vidasp.com

EX-99.2

Investor Presentation November 8, 2017

NASDAQ:CEMI

Rapid Tests for Earlier Treatment™™

Slide 2

Forward Looking Statements

Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.  Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to develop, manufacture, market and finance new products and the demand for Chembio's products.  Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Slide 3

Investment Highlights

§ A global leader in point-of-care (POC) infectious disease

– Sales & marketing organization in U.S., Europe, Africa, APAC and LATAM

– Manufacturing operations in the U.S. (Medford, NY) and Southeast Asia (Malaysia)

§ Groundbreaking patented DPP^® technology platform

– Superior sensitivity and specificity vs. traditional lateral flow technology

– Multiple tests from a tiny (10μL) drop of fingertip blood (multiplexing)

§ Robust pipeline of new DPP^® POC assays in development

– DPP^® HIV-Syphilis Combination Assay (U.S. version)

– DPP^® Fever Assays (Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa, Marburg)

– DPP^® Technology Collaborations (Traumatic Brain Injury, Cancer, Bovine TB)

§ Multiple high-value collaborations

– U.S. Government:

• HHS/ASPR/BARDA: Zika (HHS option: Zika/Dengue/Chikungunya);

• CDC: Malaria, Ebola, Zika, Zika/Dengue/Chikungunya

– Paul G. Allen Ebola Program: Fever Panel- Africa, Zika

– Bill & Melinda Gates Foundation: Malaria Oral Fluid/Saliva

– FIND: Fever Panel - Asia

Slide 4

Chembio's Dual Path Platform (DPP^®) Technology Next-Generation Point-of-Care Technology Platform

§ Patented POC technology platform

§ Improved sensitivity vs. lateral flow technology

§ Multiplex capability - multiple test results from a single patient sample

§ Adapts to multiple sample types (blood, oral fluid)

§ Application across a range of diseases and markets

§ Unique sample collection device: Sampletainer^®

See graphics

Slide 5

Chembio's Dual Path Platform (DPP^®) Technology

Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

· STD Business

· Fever Portfolio

· Technology Collaborations

DPP® Technology Platform

Slide 6

HIV Continues to be a Global Health Crisis

U.S. Syphilis Cases Increase and Risk of HIV-Syphilis Co-Infection

United States (HIV)

· ~ 1.2 million living with HIV/AIDS

· ~ 50,000 new HIV infections/year

· ~1 in 8 unaware of HIV infection

United States (SYP)

· ~63,000* new infections (2014)

Global (HIV)

· ~36.7 million living with HIV/AIDS (2015)

· ~1.1 million died of AIDS-related illnesses (2015)

Global (SYP)

· ~12 million new infections/year

*"Between 2014 and 2015, the number of reported primary and secondary (P&S) cases in the United States increased by 19%. In the United States, approximately half of men who have sex with men (MSM) with primary and secondary (P&S) syphilis were also living with HIV. In addition, MSM who are HIV-negative and diagnosed with P&S syphilis are more likely to be infected with HIV in the future." 

Source: Centers for Disease Control & Prevention (CDC) website; World Health Organization (WHO) website

Slide 7

Chembio Lateral Flow HIV Tests

Foundational HIV Product Suite

Product Features & Benefits

· FDA (PMA) approved, CLIA-waived

· CE marked, WHO pre-qualified

· 2.5 - 5.0 μL blood sample

· 15 - 20 minute test time

· Specificity: 99.9%, Sensitivity: 99.7%

Commercialization

· High quality brands, marketed globally since 2007

· Sold to Public Health Clinics, POLs, Hospitals, Self Test (EU)

· Distribution Partners US: Fisher, McKesson/PSS, H. Schein, Medline, Caribbean: Isla Lab

See graphics

Slide 8

Chembio DPP^® HIV-SYP and DPP^® HIV 1/2 Assays Strengthening our HIV/STD Portfolio

§ DPP^® HIV-Syphilis Combo Assay

– Chembio has a history of leadership

– First to receive USAID, ANVISA, COFEPRIS (Mexico) approval

– First to market/sell in Latin America

– Global screening opportunity:

– Pregnant women

– MSM (up to 70% HIV-Syphilis co-infection)

– Received CE mark (Q1 2017)

– Completed U.S. clinical trial for FDA PMA submission to be completedb during Q4'17

· DPP^® HIV 1/2 Assay

– FDA-approved (2013), CLIA-waived (2014)

                           (blood and oral fluid)

– Superior performance vs. competitors  (sensitivity)

– Patented SampleTainer® Sample Collection System

See graphics

Slide 9

Chembio's Dual Path Platform (DPP^®) Technology

Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

· STD Business

· Fever Portfolio

· Technology Collaborations

DPP® Technology Platform

Slide 10

Fever Disease – Product Development

Chembio is Collaborating with World Leading Organizations

– Bill & Melinda Gates foundation

– CDC - Center for Disease Control

– BARDA

– FIND

– Fiocruz

– The Paul G. Allen Family Foundation

See graphics

Slide 11

DPP^® Fever Disease - Product Development Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa, Marburg

DPP® Fever Panel-Africa: Collaborator: The Paul G. Allen Family Foundation (PGAFF)

DPP^® Malaria-Ebola Assay: Collaborator: CDC

DPP^® Ebola Assay: Collaborator: CDC

DPP^® Fever Panel- Asia: Collaborator: FIND

DPP^® Zika Assay: Collaborators: HHS/BARDA & The Paul G. Allen Family Foundation (PGAFF)

DPP^® Zika/Dengue/Chik Assay: Collaborator: HHS/BARDA

DPP^® Dengue Assay: Chembio Internal Development

DPP^® Chikungunya Assay: Chembio Internal Development

DPP^® Malaria OF/Saliva Assay: Collaborator: The Bill & Melinda Gates Foundation

Slide 12

Fever Diseases - A Growing Global Concern

Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa, Marburg

§ Mosquito-Borne Illnesses

– Mosquito à world's deadliest animal

– Responsible for 725,000 deaths/year

– Global geographic coverage

§ Established Fever Markets:

– Malaria: > 214 million annual infections

– Dengue: ~390 million annual infections

§ Emerging Fever Markets:

– Zika

– Chikungunya

– Ebola

– Lassa

– Marburg

§ What Crisis Will We Face Next?

Source: Centers for Disease Control & Prevention (CDC) website; World Health Organization (WHO) website

See graphics

Slide 13

Chembio is Well-Positioned to Address Zika Virus

§ Local Zika Transmission

– 2015 (Brazil) à 2017 (~60 countries)

§ Who Needs to Be Tested

– Pregnant Women

– Travelers to/from endemic Areas

– Others?

§ Molecular (MDx) Test Limitations

– Laboratory test, venous sample

– Detects acute infections only - not antibodies

– No immediate results

– High cost

§ Chembio Zika Test Advantage

– Convenience: POC Test; fingerstick sample

– Detects Antibodies (lgM/lgG)

– Time to Result: 15 minutes

– Low cost compared to MDX tests

Source: Centers for Disease Control & Prevention (CDC) website

See graphics

Slide 14

DPP^® Zika/Dengue/Chikungunya - Development Demonstrates Expertise, Efficiency and Dedication

§ DPP® Zika IgM/lgG Development/Commercialization Timeline

– Received PGAFF grant; initiated project DPP® Zika Project – 2/16

– Announced Zika collaboration with Bio-Manguinhos/Fiocruz (Brazil) – 3/16

– Completed initial testing; including 600 pregnant women – 4/16

– Announced regulatory filings with FDA-EUA, ANVISA – 5/16

– Announced regulatory filings with WHO-EUA, Cofepris, CE mark – 7/16

– Received CE mark (Europe, Caribbean)- 7/16

– Announced HHS/BARDA funding contract– 8/16

– Awarded CDC Surveillance Program: DPP® Zika/Dengue/Chikungunya (Peru, India, Guatemala, Haiti)- 9/16

– Received ANVISA approval, DPP® Zika Assay –11/16

– Successful INCQS Evaluation- 2017

See graphics

Slide 15

Chembio's Dual Path Platform (DPP^®) Technology

Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

§ STD Business

§ Fever Portfolio

§ Technology Collaborations

DPP® Technology Platform

Slide 16

Technology Collaborations:

Bio-Rad(NYSE:BIO) and DPP® Micro Reader

§ Bio-Rad Geenius™ System:   HIV-1 and HIV-2 Confirmation

– Multiplex DPP^® Assay

– Developed by Chembio

– Licensed by Bio-Rad

– Marketed/sold by Bio-Rad (ex-Brazil)

§ Chembio DPP^® Micro Reader: Quantitative Results & Data Management

– Improves DPP ^® Performance

– Provides quantitative results

– Standardizes result interpretation

– Data capture, storage, transmission

– Key features: simple, palm-sized, battery-operated, cost-effective

See graphics

Slide 17

Chembio's Dual Path Platform (DPP^®) Technology

Leveraging Our Technology Platform to Enter New Markets

§ DPP^® Cancer Assay

– Undisclosed Partner

– Biomarkers to Detect Specific Form of Cancer

– 10uL Blood Sample, 20 Minute Test

– Quantitative Result

– In development Phase

§ DPP^® TBI/Concussion Assay

– Perseus Science Group, LLC

– Biomarker to Detect TBI/Concussion

– 10uL Blood Sample, 20 Minute Test

– Quantitative Result

– In development Phase

· DPP^® BovineTB

o U.S. Department of Agriculture (USDA)

o Biomarker to detect bovine tuberculosis

o 20 minute test results

o In development phase

See graphics

Slide 18

Chembio's Global Commercial Organization Shift from Product Supply Model to Direct Sales Model

§ Regained control of U.S. HIV products (2014 – 2016)

– Terminated prior U.S. exclusive distribution agreements (HIV 1/2 STAT-PAK^® and SURE CHECK^® HIV 1/2)

§ Developed internal commercialization structure (2014 – 2016)

– Direct sales of DPP^® HIV 1/2, HIV 1/2 STAT-PAK^®, and SURE CHECK^® HIV 1/2 products in the U.S. market

§ Established geographic coverage model in U.S. (2014 – 2016)

– Established agreements with U.S. distributors (e.g., McKesson, H. Schein, Fisher, Medline)

§ Hired Experienced and Accomplished Leadership (Q4 2016)

– Robert Passas, Ph.D. – President, EMEA and APAC Regions

• Trinity Biotech; The Binding Site; Abbott, Quidel

– Sharon Klugewicz  - President, Americas Region

• Chembio COO (since 2012); Pall Corporation

§ Hired international sales executives to build commercial channels in Latin America, Africa and Asia Pacific (Q4 2016 – Q1 2017)

Slide 19

Manufacturing Capabilities

Expanding Global Manufacturing and  Distribution

Medford, NYKuala Lampur, Malaysia

o Acquired RVR Diagnostics (January 2017), Changed name to Chembio Diagnostics Malaysia Snd Bhd

o Chembio Diagnostics Malaysia, a subsidiary of Chembio Diagnostics

o International base of operations and existing sales revenue

o Cost effective manufacturing operations, ISO 13485 certification

o Strategic location in Southeast Asia provides access to new markets

o Regulatory access in Southeast Asia market

Combined Manufacturing Operations

o High volume manufacturing capabilities; current capacity 25MM tests

o 65,000 sq. ft. leased facilities (Medford, NY and Malaysia)

o Robust quality management system (Medford, NY)

o Full compliance with regulatory requirements (i.e., FDA, USDA, WHO, ISO)

o Expertise in manufacturing scale up, process validation and cGMP

o Total number of employees: ~165

Slide 20

Selected Financial Highlights

Quarter  Ended (in 000's)       9 Months Ended (in 000's)

	Sept. 30, 2017			Sept. 30, 2016			Sept. 30, 2017			Sept. 30, 2016
Net Product Revenues	$	6,133		$	2,502		$	14,453		$	10,452
Total Revenues	$	7,587		$	3,746		$	18,027		$	13,614
Gross Margin	$	3,523		$	1,952		$	8,539		$	6,698
Loss from Operations	$	(589	)	$	(2,144	)	$	(4,398	)	$	(4,998	)
Net Loss	$	(585	)		(2,138	)		(4,373	)	$	(10,879	)*
Accounts Receivable Net	$	5,768		$	4,208		$	5,768		$	4,208
Cash (as of end of period)	$	1,872		$	12.172		$	1,872		$	12,172

Slide 21

Experienced Executive Leadership Team

Executive:  John J. Sperzel III,   President &CEO

Joined Chembio: 2014

Previous Experience: 2011-2013, President and CEO of ITC/Accriva; 1987-2011 Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim

Executive:  Richard Larkin, CPA  Chief Financial Officer; Executive Vice President

Joined Chembio: 2003

Previous Experience: 2000-2003  CFO of Visual Technology Group; 1987-2000 CFO of Protex  International Corp.

Executive:  Javan Esfandiari, M.S.  Chief Science and Technology Officer; Executive Vice President

Joined Chembio:  2000

Previous Experience: 1997-2000, Co-founder of Sinovus Biotech AB (Sweden), acquired by Chembio in 2000; 1993-1997 R&D Director of On-Site Biotech

Executive:  Sharon Klugewicz, M.S., President, Americas Region

Joined Chembio: 2012

Previous Experience: 2009-2012, Sr. VP Scientific & Laboratory Services of Pall Corporation; 1991-2009 Pall Corporation

Executive:  Robert Passas, Ph.D., President, EMEA & APAC Regions

Joined Chembio:  2016

Previous Experience: 2015-2016, VP, Worldwide Marketing and International Sales at Trinity Biotech; 1993-2015  The Binding Site, Abbott, Trinity Biotech, Quidel

Executive:  Thomas Ippolito, VP Regulatory & Clinical Affairs

Joined Chembio: 2005

Previous Experience: 2000-2005, VP Quality & Regulatory of Biospecific Technologies Corp.; 1984-2000 United Biomedical Inc., Analytab Products Inc. and Eastern Long Island Hospital

Executive:  Paul Lambotte, Ph.D, VP Product Development

Joined Chembio: 2014

Previous Experience: 2009 – 2014, President of PLC Inc.; 2009 – 2012 Chief Science Officer of Axxin Pty Ltd.; 2000-2009, VP of R&D and Business Development of Quidel, Inc.

Executive:  David Gyorke, VP Manufacturing Operations

Joined Chembio: 2017

Previous Experience: 2011-2016, VP operations of Nanomix, 1983-2011, NeoVista, Farallon Medical, Inc., Cholestech Corporation, Bio-Rad